Plasma Kallikrein/KLKB1产品信息
英文名称:Plasma kallikrein
中文名称:血浆激肽释放酶
靶点别称:Fletcher factor,kallikrein B, plasma (Fletcher factor) 1,kininogenin,KLK3plasma kallikrein,KLKB1,plasma kallikrein heavy chain,plasma kallikrein light chain,Plasma Kallikrein,Plasma Prekallikrein,PPK,KLKB1
物种:Human/Mouse
属性:Protein
标记:Unconjugated
内毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
纯度(Purity)
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制剂(Formulation)
Supplied as 0.2 μm filtered solution in 50mM Tris 150mM NaCl, PH7.5 with glycerol as protectant.
Contact us for customized product form or formulation.
运输(Shipping)
This product is supplied and shipped with dry ice, please inquire the shipping cost.
存储(Storage)
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
The product MUST be stored at -70°C or lower upon receipt;
-70°C for 3 months under sterile conditions.
Plasma Kallikrein/KLKB1分子背景
Human Plasma Kallikrein, a serine protease, is synthesized in the liver and circulates in the plasma by binding to high molecular weight (HMW) kininogen or as a free zymogen. The enzyme cleaves Lys-Arg and Arg-Ser bonds. It activates, in a reciprocal reaction, factor XII after its binding to a negatively charged surface. It also releases bradykinin from HMW kininogen and may also play a role in the renin-angiotensin system by converting prorenin into renin.
关键字: 血浆激肽释放酶;Plasma kallikrein;KLKB1;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group(股票代码:301080)是成立于2010年的跨国生物科技公司,是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球,横跨亚洲、北美洲、欧洲,在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家,与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。